ESMO Virtual 2020: Circulating tumour DNA in metastatic kidney cancer patients

In a paper presented at this year’s European Society of Medical Oncology (ESMO) 2020 virtual congress, Dr Zeynep Zengin from City of Hope Hospital, Los Angeles, USA presented the results of a study using a commercially available circulating tumour DNA (ctDNA) assay. Assessment of ctDNA is a non-invasive method to assess genetic alterations in tumours. […]

read more

ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer

Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were presented at the European Sociaety of Medical Oncology (ESMO) virtual congress. The study showed clinical evidence that biomarker-guided first-line therapy could be used to enrich responses in patients with metastatic clear cell renal cell carcinoma (RCC). The trial included 154 patients treated with nivolumab or […]

read more

ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer

At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Cristina Suarez from the Hospital Universitari Vall D’Hebron and Vall D’Hebron Institute of Oncology in Barcelona, Spain presented an update of the clinical data from the phase 2 study of oral HIF-2a MK-6482 in Von Hippel-Lindau disease-associated cancers. Von Hippel-Lindau disease is a […]

read more

ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer

Non-clear cell renal cell carcinoma (RCC) accounts for about 25% of all RCC diagnoses and usually has worse outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have shown preliminary activity in non-clear cell RCC. Cabozantinib appears to enhance the response to immune checkpoint inhibitors and has shown encouraging results in combination with […]

read more

ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer

At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Choueiri from Dana Farber Cancer Institute in Boston, USA presented the results of the phase 3 CheckMate-9ER trial evaluating the combination of nivolumab and cabozantinib compared to sunitinib in the first-line treatment of patients with advanced or metastatic renal cell carcinoma (RCC). Each […]

read more

PBRM1 as a biomarker for kidney cancer

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Centre in Texas, USA, talks about the use of PBRM1 as a potential biomarker for immune response to checkpoint inhibitors. The data for this biomarker is controversial and complicated and in the future researchers need to better understand how this relates to treatment response. […]

read more

ESMO Virtual 2020: Treatment-free survival after immunotherapy vs. targeted therapy for advanced kidney cancer

Over the past 2 years, the use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has become the standard of care for these patients. The first combination was nivolumab plus ipilimumab, which demonstrated a survival benefit over sunitinib in patients with intermediate and poor risk metastatic RCC (CheckMate-214). Shortly after, […]

read more

ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer

Over the past 2 years, the use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has become the standard of care for these patients. The first combination was nivolumab plus ipilimumab, which demonstrated a survival benefit over sunitinib in patients with intermediate and poor risk metastatic RCC (CheckMate-214). Shortly after, […]

read more

Sapanisertib is tolerable and shows activity in advanced kidney cancer

In a phase I study to look at the safety and tolerability of a new drug called sapanisertib, sapanisertib was well-tolerated and showed some anti-tumour activity in patients with renal cell carcinoma (RCC) and endometrial cancer. Sapanisertib is an oral, highly selective inhibitor of the mTORC1/mTORC2 receptors in advanced solid tumours. In the study, 82 […]

read more

GRANT score for predicting disease-free survival in kidney cancer

In this retrospective study conducted at various hospitals in Italy, the GRANT (GRade, Age, Nodes, and Tumour) and the UISS (University of California Los Angeles Integrated Staging System) scores were compared in 134 patients with renal cell carcinoma (RCC) who had a nephrectomy. These scores are used to predict outcomes in patients with localised RCC. […]

read more
Showing 1 to 10 of 682 results
  TOP